Registry update — unassessed
A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement
Trial registry update: COMPLETED. No results reported in the supplied registry record.
RCTN=30Notable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 30, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- The study provides no reported findings, so it cannot demonstrate whether metformin or the combination regimens affect healthspan or longevity markers.
- The small sample size (approximately 10 per arm) and short 90-day duration limit generalizability and ability to detect meaningful effects on aging outcomes.
- The combinatorial design confounds individual drug effects, making it impossible to isolate metformin's contribution to any observed outcome.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 30
- Duration
- 3 months
- Population
- Up to 30 subjects, demographics not specified
- Primary outcome
- Longevity-related outcomes (not specified)
- Effect size
- —
- Significance
- Not reported
- Journal
- AgelessRx
- Published
- Oct 30, 2026
Sources
Primary source
- AgelessRx ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 2. This is not a claim of full-text review.
A 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes
a small sample size of up to 30 subjects (10 subjects in each arm) will be randomized into one of the three arms: 1) Control, 2) Multi-therapy (B12, Naltrexone, Metformin, and NAD+), or 3) Comprehensive Therapy (Rapamycin, Naltrexone, Metformin, B12, NAD+, GSH, and Infinite Supplement)
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.